micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr

Did you know? The World Health Organization (WHO) considers an intervention cost-effective if it costs three times a person’s income per quality-adjusted life year (QALY) gained. In the U.S., with an average income of around $40,000, this means interventions costing less than $120,000 per QALY are deemed cost-effective. Harvard economist David Cutler suggests $100,000 as a reasonable benchmark.

How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?

background

How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?

Profile Image
  • Saved

1yr
Innovative Cardiovascular Research Insights at AHA’s 100th Anniversary

At the American Heart Association’s centennial conference, Dr. Amit Khera, Director of Preventive Cardiology and Professor at UT Southwestern Medical Center, and Dr. John L. Sapp, Assistant Dean of Clinical Research at Dalhousie University, presented key findings. Topics included Tirzepatide’s impact on HFpEF and obesity, the comparison of left atrial appendage closure versus anticoagulation for atrial fibrillation, intensive blood pressure control in diabetes, and insights from the VANISH2 trial on ventricular tachycardia. These findings provide healthcare professionals with evidence-based strategies to advance cardiovascular care.

Profile Image
  • Saved

1yr
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN - PubMed

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38598969/

Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment...

Homozygous familial hypercholesterolemia requires early lipid-lowering treatment. Lipoprotein apheresis effectively reduces LDL-C, but guidelines are limited. A consensus statement offers practical guidance on its use in children with this condition.

Profile Image
  • Saved

1yr
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review - PubMed

Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38265575/

Based on reported willingness to pay thresholds for each setting, most CEA studies concluded that screening for FH compared with no screening was cost-effective, regardless of the screening strategy. Cascade...

This review synthesizes cost-effectiveness of familial hypercholesterolemia screening strategies, finding cascade screening most cost-effective, with long-term lipid-lowering treatment costs as a key ICER driver. Most strategies were cost-effective compared to no screening.

Profile Image
  • Saved

1yr
American Heart Association Scientific Sessions

The American Heart Association 2024 Scientific Sessions were held at the McCormick Place Convention Center in Chicago from Nov. 16 to 18. More than 15,000 attendees were at the meeting via virtual stream or in-person. Click above to find our postconference wrap-up report with insights on new therapies and advances in preventing, diagnosing, and treating cardiovascular disease.